<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01293006</url>
  </required_header>
  <id_info>
    <org_study_id>4305-032</org_study_id>
    <nct_id>NCT01293006</nct_id>
  </id_info>
  <brief_title>Effects of Suvorexant in Patients With Chronic Obstructive Pulmonary Disease (MK-4305-032)</brief_title>
  <official_title>A Study to Evaluate the Effects of MK-4305 in Patients With Chronic Obstructive Pulmonary Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety, tolerability, and effect of multiple doses of suvorexant
      (MK-4305) on respiratory function in participants with chronic obstructive pulmonary disease
      (COPD). This is a crossover study, so all participants will receive both suvorexant and
      placebo while on study. The primary hypothesis of this study is that multiple doses of
      suvorexant do not produce a clinically significant reduction of mean oxygen saturation (SaO2)
      during total sleep time in participants with COPD, as compared to placebo.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 25, 2011</start_date>
  <completion_date type="Actual">February 22, 2012</completion_date>
  <primary_completion_date type="Actual">January 20, 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Arterial Oxygen Saturation (SaO2) During Total Sleep Time</measure>
    <time_frame>Day 4 of each period</time_frame>
    <description>Evaluation of the effect of multiple dose suvorexant (MK-4305) on SaO2 during total sleep time as measured by pulse oximetry. Lower SaO2 values are associated with sleep impairment. Total sleep time is the total of all rapid eye movement (REM) and non-REM sleep in a sleep episode.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>Up to 14 days after last dose</time_frame>
    <description>An adverse event (AE) is any unfavorable and unintended change in the structure, function or chemistry of the body temporally associated with study drug administration whether or not considered related to the use of the product.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Discontinued From Study Drug Due to an AE</measure>
    <time_frame>Up to 15 days</time_frame>
    <description>An AE is any unfavorable and unintended change in the structure, function or chemistry of the body temporally associated with study drug administration whether or not considered related to the use of the product.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Total Sleep Time in Which SaO2 is Less Than 90%, 85% or 80%</measure>
    <time_frame>Day 1 and Day 4 of each period</time_frame>
    <description>Evaluation of the percentage of the night in which SaO2 is less than 90%, less than 85% and less than 80% following multiple dose administration of suvorexant and placebo. Lower SaO2 values are associated with sleep impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Apnea/Hypopnea Index (AHI)</measure>
    <time_frame>Day 1 and Day 4 of each period</time_frame>
    <description>Evaluation of the effect of multiple dose administration of suvorexant on AHI as measured by polysomnography. The AHI is an overall index of obstructive sleep apnea (OSA) severity. The AHI is calculated by dividing the number of apneas and hypopneas by the number of hours of sleep. AHI values are categorized as mild OSA = 5 to &lt;15/hr and moderate OSA = 15 to &lt;30/hr.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Arterial SaO2 for Different Sleep Stages</measure>
    <time_frame>Day 1 and Day 4 of each period</time_frame>
    <description>Comparison of the mean SaO2 during different sleep stages (REM, Non-REM, and awake) following multiple dose administration of suvorexant and placebo. Lower SaO2 values are associated with sleep impairment. Sleep stages were determined by polysomnography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Arterial SaO2 During Total Sleep Time</measure>
    <time_frame>Day 1 of each period</time_frame>
    <description>Evaluation of the effect of multiple dose suvorexant on mean oxygen saturation (SaO2) during total sleep time as measured by pulse oximetry. Lower SaO2 values are associated with sleep impairment. Total sleep time is the total of all rapid eye movement (REM) and non-REM sleep in a sleep episode.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Insomnia</condition>
  <arm_group>
    <arm_group_label>Suvorexant first, then placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During Period 1, participants &lt;65 years of age were administered a 40-mg oral dose of suvorexant once daily for 4 consecutive days in the evening and participants ≥65 years of age were administered a 30-mg oral dose of
suvorexant once daily for 4 consecutive days in the evening. A washout period of at least 7 days followed Period 1. During Period 2, participants received one placebo tablet matching suvorexant, orally, once daily for 4 consecutive days in the evening.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo first, then suvorexant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During Period 1, participants &lt;65 years of age received one placebo tablet matching suvorexant, orally, once daily for 4 consecutive days in the evening and participants ≥65 years of age received one placebo tablet matching
suvorexant, orally, once daily for 4 consecutive days in the evening. A washout period of at least 7 days followed Period 1. During Period 2, participants were administered a 40-mg oral dose of suvorexant once daily for 4 consecutive days in the evening.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>suvorexant</intervention_name>
    <description>one tablet (30 or 40 mg suvorexant depending on participant age: 40 mg for participants &lt;65 years of age and 30 mg for participants ≥65 years of age), orally, once daily, for 4 consecutive days</description>
    <arm_group_label>Suvorexant first, then placebo</arm_group_label>
    <arm_group_label>Placebo first, then suvorexant</arm_group_label>
    <other_name>MK-4305</other_name>
    <other_name>SCH 900433</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>one tablet matching suvorexant, orally, once daily, for 4 consecutive days</description>
    <arm_group_label>Suvorexant first, then placebo</arm_group_label>
    <arm_group_label>Placebo first, then suvorexant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female participants of reproductive potential must demonstrate a serum beta-human
             chorionic gonadotropin (β-hCG) level consistent with the nongravid state at the
             prestudy (screening) visit and agree to use (and/or have their partner use) two (2)
             acceptable methods of birth control beginning at the prestudy visit throughout the
             study (including washout intervals between treatment periods/panels) and until 2 weeks
             after the last dose of study drug in the last treatment period. Females of
             non-childbearing potential (postmenopausal without menses for at least 1 year and
             follicle stimulating hormone [FSH] value in the postmenopausal range, or status post
             hysterectomy, oophorectomy or tubal ligation. Documented hysterectomy or oophorectomy)

          -  Body Mass Index (BMI) ≤40 kg/m2 at the prestudy (screening)

          -  COPD documented by medical history and pulmonary function tests with spirometry
             measurements at Visit 1 meet all of the following COPD study criteria according to the
             modified Global Initiative for Obstructive Lung Disease (GOLD) criteria (forced
             expiratory volume [FEV1]/ forced vital capacity [FVC] ratio ≤70% and FEV1 ≥40%
             predicted [inclusive])

          -  Stable physical health for at least 2 weeks prior to entering the study

          -  No clinically significant abnormality on electrocardiogram (ECG)

          -  No clinically significant abnormality on the screening polysomnography (PSG) including
             no evidence of obstructive sleep apnea, restless leg syndrome, periodic limb movement
             disorder, parasomnia including nightmare disorder, sleep terror disorder and
             sleepwalking disorder but participants with insomnia may be enrolled

          -  Nonsmoker or smokes ≤20 cigarettes or equivalent per day without the urge to wake up
             to smoke during the night

          -  Sleeps for 4 hours or more per night with a usual bedtime between 8:00 post meridian
             (PM) and 12:30 ante meridian (AM)

          -  Participant must complete a sleep diary for at least 5 consecutive days and up to 21
             days prior to the screening PSG visit

          -  Participant is reliably able to perform the study assessments; demonstrates ability to
             understand task instructions, and is physically capable

        Exclusion Criteria:

          -  Participant is mentally or legally incapacitated, has significant emotional problems
             at the time of prestudy or expected during conduct of the study, or has a history or
             evidence of a clinically significant psychiatric disorder that would interfere with
             participation in the study

          -  Abnormal pre-randomization laboratory values in alanine transaminase (ALT &gt;1.5 x the
             upper limit of normal [ULN]), aspartate transaminase (AST &gt;1.5 x ULN), total bilirubin
             &gt;1.5 x ULN, and serum creatinine of &gt;2 mg/dL

          -  Participant has any history of a neurological disorder, including but not limited to
             seizure disorder (other than single episodes of childhood febrile seizures), stroke,
             transient ischemic attack, multiple sclerosis, cognitive impairment, or significant
             head trauma with sustained loss of consciousness within the last 10 years

          -  History of bipolar disorder, a psychotic disorder, or posttraumatic stress disorder,
             or psychiatric condition requiring treatment with a prohibited medication, or
             psychiatric condition that, in the investigator's opinion, would interfere with the
             patient's ability to participate in the study

          -  Participant has other than COPD and evidence of another clinically significant, active
             pulmonary disorder, such as such as bronchiectasis or asthma documented by history,
             physical examination, or chest x‑ray

          -  History within the past 6 months prior to the prestudy of acute coronary syndrome,
             unstable angina, congestive heart failure, cardiogenic syncope, cardiomyopathy, any
             symptomatic arrhythmia, orthostatic hypotension, or uncontrolled hypertension

          -  History of neoplastic disease except adequately treated non-melanomatous skin
             carcinoma or carcinoma in situ of the cervix, malignancies which have been
             successfully treated ≥10 years prior to the prestudy and follow-up has revealed no
             evidence of recurrence from the time of treatment through the time of the prestudy, or
             in the opinion of the Investigator, are highly unlikely to sustain a recurrence for
             the duration of the study

          -  History or diagnosis of narcolepsy, cataplexy (familial or idiopathic), circadian
             rhythm sleep disorder, parasomnia including nightmare disorder, sleep terror disorder,
             sleepwalking disorder, and REM behavior disorder, sleep-related Breathing Disorder
             (i.e., obstructive or central sleep apnea syndrome or central alveolar hypoventilation
             syndrome), periodic limb movement disorder, restless legs syndrome, or primary
             hypersomnia

          -  Normal PSG recording at screening

          -  Hematocrit &gt; 55%

          -  Participant has been treated in an emergency room or has been hospitalized for COPD
             within 2 months prior to the screening visit, necessitating antibiotics, systemic
             corticosteroids, oxygen therapy

          -  Positive screening urine alcohol test or drug test

          -  Nursing mother

          -  Condition, therapy, lab, or ECG abnormality or other circumstances that might confound
             the results of the study

          -  Taking, or plans to take, one or more of the prohibited concomitant medications

          -  Participant consumes excessive amounts of alcohol, defined as greater than 3 glasses
             of alcoholic beverages, or excessive amounts, defined as greater than 6 servings (1
             serving is approximately equivalent to 120 mg of caffeine) of coffee, tea, cola, or
             other caffeinated beverages per day

          -  Participant has had major surgery, donated or lost 1 unit of blood (approximately 500
             mL) or participated in another investigational study within 4 weeks prior to the
             prestudy (screening) visit

          -  History of significant multiple and/or severe allergies (including latex allergy), or
             has had an anaphylactic reaction or significant intolerability to prescription or
             non-prescription drugs or food

          -  Currently a regular user (including &quot;recreational use&quot;) of any illicit drugs or has a
             history of drug (including alcohol) abuse within approximately 2 years

          -  Need for more than 3 toilet visits during the night

          -  Participant has a history of shift work (defined as permanent night shift or rotating
             day/night shift work) within the past 2 weeks or anticipates the need to perform shift
             work during the study

          -  Travel across 3 or more time zones (transmeridian travel) within 1 week of study start

          -  Participant is at imminent risk of self-harm or harm to others in the investigator's
             opinion

          -  Concerns of the investigator regarding the safe participation of the participant in
             the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Sun H, Palcza J, Rosenberg R, Kryger M, Siringhaus T, Rowe J, Lines C, Wagner JA, Troyer MD. Effects of suvorexant, an orexin receptor antagonist, on breathing during sleep in patients with chronic obstructive pulmonary disease. Respir Med. 2015 Mar;109(3):416-26. doi: 10.1016/j.rmed.2014.12.010. Epub 2015 Jan 5.</citation>
    <PMID>25661282</PMID>
  </results_reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 8, 2011</study_first_submitted>
  <study_first_submitted_qc>February 9, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2011</study_first_posted>
  <results_first_submitted>August 19, 2014</results_first_submitted>
  <results_first_submitted_qc>September 8, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 10, 2014</results_first_posted>
  <last_update_submitted>June 1, 2017</last_update_submitted>
  <last_update_submitted_qc>June 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pulmonary Disease, Chronic Obstructive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Suvorexant</mesh_term>
  </intervention_browse>
  <study_docs>
    <study_doc>
      <doc_type>CSR Synopsis</doc_type>
      <doc_url>http://www.merck.com/clinical-trials/study.html?id=4305-032&amp;kw=4305-032&amp;tab=access</doc_url>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Suvorexant (40 mg) Then Placebo</title>
          <description>During Period 1, participants &lt;65 years of age were administered a 40-mg oral dose of suvorexant once daily for 4 consecutive days in the evening. A washout period of at least 7 days followed Period 1. During Period 2, participants received one placebo tablet matching suvorexant, orally, once daily for 4 consecutive days in the evening.</description>
        </group>
        <group group_id="P2">
          <title>Suvorexant (30 mg) Then Placebo</title>
          <description>During Period 1, participants ≥65 years of age were administered a 30-mg oral dose of suvorexant once daily for 4 consecutive days in the evening. A washout period of at least 7 days followed Period 1. During Period 2, participants received one placebo tablet matching suvorexant, orally, once daily for 4 consecutive days in the evening.</description>
        </group>
        <group group_id="P3">
          <title>Placebo Then Suvorexant (40 mg)</title>
          <description>During Period 1, participants &lt;65 years of age received one placebo tablet matching suvorexant, orally, once daily for 4 consecutive days in the evening. A washout period of at least 7 days followed Period 1. During Period 2, participants were administered a 40-mg oral dose of suvorexant once daily for 4 consecutive days in the evening.</description>
        </group>
        <group group_id="P4">
          <title>Placebo Then Suvorexant (30 mg)</title>
          <description>During Period 1, participants ≥65 years of age received one placebo tablet matching suvorexant, orally, once daily for 4 consecutive days in the evening. A washout period of at least 7 days followed Period 1. During Period 2, participants were administered a 30-mg oral dose of suvorexant once daily for 4 consecutive days in the evening.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Suvorexant (40 mg) Then Placebo</title>
          <description>During Period 1, participants &lt;65 years of age were administered a 40-mg oral dose of suvorexant once daily for 4 consecutive days in the evening. A washout period of, at least, 7 days followed Period 1. During Period 2, participants received one placebo tablet matching suvorexant, orally, once daily for 4 consecutive days in the evening.</description>
        </group>
        <group group_id="B2">
          <title>Suvorexant (30 mg) Then Placebo</title>
          <description>During Period 1, participants ≥65 years of age were administered a 30-mg oral dose of MK-suvorexant once daily for 4 consecutive days in the evening. A washout period of at least 7 days followed Period 1. During Period 2, participants received one placebo tablet matching suvorexant, orally, once daily for 4 consecutive days in the evening.</description>
        </group>
        <group group_id="B3">
          <title>Placebo Then Suvorexant (40 mg)</title>
          <description>During Period 1, participants &lt;65 years of age received one placebo tablet matching suvorexant, orally, once daily for 4 consecutive days in the evening. A washout period of at least 7 days followed Period 1. During Period 2, participants were administered a 40-mg oral dose of suvorexant once daily for 4 consecutive days in the evening.</description>
        </group>
        <group group_id="B4">
          <title>Placebo Then Suvorexant (30 mg)</title>
          <description>During Period 1, participants ≥65 years of age received one placebo tablet matching suvorexant, orally, once daily for 4 consecutive days in the evening. A washout period of at least 7 days followed Period 1. During Period 2, participants were administered a 30-mg oral dose of suvorexant once daily for 4 consecutive days in the evening.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="9"/>
            <count group_id="B4" value="3"/>
            <count group_id="B5" value="25"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.9" lower_limit="39" upper_limit="64"/>
                    <measurement group_id="B2" value="67.0" lower_limit="67" upper_limit="67"/>
                    <measurement group_id="B3" value="56.7" lower_limit="47" upper_limit="64"/>
                    <measurement group_id="B4" value="70.3" lower_limit="69" upper_limit="72"/>
                    <measurement group_id="B5" value="58.2" lower_limit="39" upper_limit="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Arterial Oxygen Saturation (SaO2) During Total Sleep Time</title>
        <description>Evaluation of the effect of multiple dose suvorexant (MK-4305) on SaO2 during total sleep time as measured by pulse oximetry. Lower SaO2 values are associated with sleep impairment. Total sleep time is the total of all rapid eye movement (REM) and non-REM sleep in a sleep episode.</description>
        <time_frame>Day 4 of each period</time_frame>
        <population>Twenty-four of the 25 participants were included in the primary evaluation of SaO2 and AHI data; one participant was excluded due to a protocol violation. During the Placebo periods, there were 22 evaluable participants at Day 4; 2 participants had either no data or missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Suvorexant (30 mg or 40 mg)</title>
            <description>Participants administered either a 40-mg or a 30-mg oral dose of suvorexant.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants administered placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Arterial Oxygen Saturation (SaO2) During Total Sleep Time</title>
          <description>Evaluation of the effect of multiple dose suvorexant (MK-4305) on SaO2 during total sleep time as measured by pulse oximetry. Lower SaO2 values are associated with sleep impairment. Total sleep time is the total of all rapid eye movement (REM) and non-REM sleep in a sleep episode.</description>
          <population>Twenty-four of the 25 participants were included in the primary evaluation of SaO2 and AHI data; one participant was excluded due to a protocol violation. During the Placebo periods, there were 22 evaluable participants at Day 4; 2 participants had either no data or missing data.</population>
          <units>Percentage of Oxygen Saturation</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.38" lower_limit="92.47" upper_limit="94.30"/>
                    <measurement group_id="O2" value="92.99" lower_limit="92.06" upper_limit="93.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Difference (Suvorexant - Placebo) of Least Squares Means</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.39</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.12</ci_lower_limit>
            <ci_upper_limit>0.91</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adverse Events</title>
        <description>An adverse event (AE) is any unfavorable and unintended change in the structure, function or chemistry of the body temporally associated with study drug administration whether or not considered related to the use of the product.</description>
        <time_frame>Up to 14 days after last dose</time_frame>
        <population>All participants were included in the Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Suvorexant (40 mg)</title>
            <description>Participants administered a 40-mg oral dose of suvorexant.</description>
          </group>
          <group group_id="O2">
            <title>Suvorexant (30 mg)</title>
            <description>Participants administered a 30-mg oral dose of suvorexant.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants administered placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events</title>
          <description>An adverse event (AE) is any unfavorable and unintended change in the structure, function or chemistry of the body temporally associated with study drug administration whether or not considered related to the use of the product.</description>
          <population>All participants were included in the Safety Population.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Discontinued From Study Drug Due to an AE</title>
        <description>An AE is any unfavorable and unintended change in the structure, function or chemistry of the body temporally associated with study drug administration whether or not considered related to the use of the product.</description>
        <time_frame>Up to 15 days</time_frame>
        <population>All participants were included in the Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Suvorexant (40 mg)</title>
            <description>Participants administered a 40-mg oral dose of suvorexant.</description>
          </group>
          <group group_id="O2">
            <title>Suvorexant (30 mg)</title>
            <description>Participants administered a 30-mg oral dose of suvorexant.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants administered placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Discontinued From Study Drug Due to an AE</title>
          <description>An AE is any unfavorable and unintended change in the structure, function or chemistry of the body temporally associated with study drug administration whether or not considered related to the use of the product.</description>
          <population>All participants were included in the Safety Population.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Total Sleep Time in Which SaO2 is Less Than 90%, 85% or 80%</title>
        <description>Evaluation of the percentage of the night in which SaO2 is less than 90%, less than 85% and less than 80% following multiple dose administration of suvorexant and placebo. Lower SaO2 values are associated with sleep impairment.</description>
        <time_frame>Day 1 and Day 4 of each period</time_frame>
        <population>Twenty-four of the 25 participants were included in the primary evaluation of SaO2 and AHI data; one participant was excluded due to a protocol violation. During the Placebo periods, there were 22 evaluable participants at Day 4; 2 participants had either no data or missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Suvorexant (30 mg or 40 mg)</title>
            <description>Participants receiving either a 40-mg or 30-mg dose of suvorexant.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants receiving placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Total Sleep Time in Which SaO2 is Less Than 90%, 85% or 80%</title>
          <description>Evaluation of the percentage of the night in which SaO2 is less than 90%, less than 85% and less than 80% following multiple dose administration of suvorexant and placebo. Lower SaO2 values are associated with sleep impairment.</description>
          <population>Twenty-four of the 25 participants were included in the primary evaluation of SaO2 and AHI data; one participant was excluded due to a protocol violation. During the Placebo periods, there were 22 evaluable participants at Day 4; 2 participants had either no data or missing data.</population>
          <units>Percentage of Total Sleep Time</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (SaO2 is less than 90%) (n = 24, 24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.01" lower_limit="-1.48" upper_limit="13.49"/>
                    <measurement group_id="O2" value="4.98" lower_limit="-2.51" upper_limit="12.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 (SaO2 is less than 85%) (n = 24, 24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.32" lower_limit="-0.03" upper_limit="0.67"/>
                    <measurement group_id="O2" value="0.11" lower_limit="-0.24" upper_limit="0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 (SaO2 is less than 80%) (n = 24, 24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Due to the small number of participants experiencing SaO2 less than 80%, a formal statistical analysis was not conducted.</measurement>
                    <measurement group_id="O2" value="NA">Due to the small number of participants experiencing SaO2 less than 80%, a formal statistical analysis was not conducted.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4 (SaO2 is less than 90%) (n = 24, 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.45" lower_limit="0.01" upper_limit="14.89"/>
                    <measurement group_id="O2" value="6.63" lower_limit="-1.05" upper_limit="14.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4 (SaO2 is less than 85%) (n = 24, 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.32" lower_limit="0.06" upper_limit="0.58"/>
                    <measurement group_id="O2" value="0.01" lower_limit="-0.26" upper_limit="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4 (SaO2 is less than 80%) (n = 24, 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Due to the small number of participants experiencing SaO2 less than 80%, a formal statistical analysis was not conducted.</measurement>
                    <measurement group_id="O2" value="NA">Due to the small number of participants experiencing SaO2 less than 80%, a formal statistical analysis was not conducted.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 1, SaO2 &lt;90%, Difference (Suvorexant - Placebo) of Least Squares Means</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.03</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.30</ci_lower_limit>
            <ci_upper_limit>3.36</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 1, SaO2 &lt;85%, Difference (Suvorexant - Placebo) of Least Squares Means</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.21</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.08</ci_lower_limit>
            <ci_upper_limit>0.50</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 4, SaO2 &lt;90%, Difference (Suvorexant - Placebo) of Least Squares Means</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.82</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.77</ci_lower_limit>
            <ci_upper_limit>7.41</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 4, SaO2 &lt;85%, Difference (Suvorexant - Placebo) of Least Squares Means</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.32</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.00</ci_lower_limit>
            <ci_upper_limit>0.63</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Apnea/Hypopnea Index (AHI)</title>
        <description>Evaluation of the effect of multiple dose administration of suvorexant on AHI as measured by polysomnography. The AHI is an overall index of obstructive sleep apnea (OSA) severity. The AHI is calculated by dividing the number of apneas and hypopneas by the number of hours of sleep. AHI values are categorized as mild OSA = 5 to &lt;15/hr and moderate OSA = 15 to &lt;30/hr.</description>
        <time_frame>Day 1 and Day 4 of each period</time_frame>
        <population>Twenty-four of the 25 participants were included in the primary evaluation of SaO2 and AHI data; one participant was excluded due to a protocol violation. During the Placebo periods, there were 22 evaluable participants at Day 4; 2 participants had either no data or missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Suvorexant (30 mg or 40 mg)</title>
            <description>Participants administered either a 40-mg or 30-mg dose of suvorexant.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants administered placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Apnea/Hypopnea Index (AHI)</title>
          <description>Evaluation of the effect of multiple dose administration of suvorexant on AHI as measured by polysomnography. The AHI is an overall index of obstructive sleep apnea (OSA) severity. The AHI is calculated by dividing the number of apneas and hypopneas by the number of hours of sleep. AHI values are categorized as mild OSA = 5 to &lt;15/hr and moderate OSA = 15 to &lt;30/hr.</description>
          <population>Twenty-four of the 25 participants were included in the primary evaluation of SaO2 and AHI data; one participant was excluded due to a protocol violation. During the Placebo periods, there were 22 evaluable participants at Day 4; 2 participants had either no data or missing data.</population>
          <units>Events per hour</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (n = 24, 24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.64" lower_limit="4.63" upper_limit="8.66"/>
                    <measurement group_id="O2" value="5.92" lower_limit="3.91" upper_limit="7.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4 (n = 24, 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.27" lower_limit="5.71" upper_limit="10.84"/>
                    <measurement group_id="O2" value="6.22" lower_limit="3.61" upper_limit="8.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 1, Difference (Suvorexant - Placebo) of Least Squares Means</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.72</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.60</ci_lower_limit>
            <ci_upper_limit>2.04</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 4, Difference (Suvorexant - Placebo) of Least Squares Means</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.05</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.33</ci_lower_limit>
            <ci_upper_limit>3.77</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Arterial SaO2 for Different Sleep Stages</title>
        <description>Comparison of the mean SaO2 during different sleep stages (REM, Non-REM, and awake) following multiple dose administration of suvorexant and placebo. Lower SaO2 values are associated with sleep impairment. Sleep stages were determined by polysomnography.</description>
        <time_frame>Day 1 and Day 4 of each period</time_frame>
        <population>Twenty-four of the 25 participants were included in the primary evaluation of SaO2 and AHI data; one participant was excluded due to a protocol violation. During the Placebo periods, there were 22 evaluable participants at Day 4; 2 participants had either no data or missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Suvorexant (30 mg or 40 mg)</title>
            <description>Participants administered either a 40-mg or a 30-mg dose of suvorexant.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants administered placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Arterial SaO2 for Different Sleep Stages</title>
          <description>Comparison of the mean SaO2 during different sleep stages (REM, Non-REM, and awake) following multiple dose administration of suvorexant and placebo. Lower SaO2 values are associated with sleep impairment. Sleep stages were determined by polysomnography.</description>
          <population>Twenty-four of the 25 participants were included in the primary evaluation of SaO2 and AHI data; one participant was excluded due to a protocol violation. During the Placebo periods, there were 22 evaluable participants at Day 4; 2 participants had either no data or missing data.</population>
          <units>Percentage of Oxygen Saturation</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 - Mean SaO2 during REM (n = 24, 24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.06" lower_limit="92.12" upper_limit="94.00"/>
                    <measurement group_id="O2" value="93.02" lower_limit="92.08" upper_limit="93.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 - Mean SaO2 during Non-REM (n = 24, 24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.14" lower_limit="92.26" upper_limit="94.02"/>
                    <measurement group_id="O2" value="93.27" lower_limit="92.39" upper_limit="94.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 - Mean SaO2 during Wake (n = 24, 24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.15" lower_limit="93.42" upper_limit="94.89"/>
                    <measurement group_id="O2" value="94.37" lower_limit="93.63" upper_limit="95.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4 - Mean SaO2 during REM (n = 24, 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.21" lower_limit="92.23" upper_limit="94.19"/>
                    <measurement group_id="O2" value="92.88" lower_limit="91.88" upper_limit="93.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4 - Mean SaO2 during Non-REM (n = 24, 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.35" lower_limit="92.40" upper_limit="94.30"/>
                    <measurement group_id="O2" value="93.09" lower_limit="92.13" upper_limit="94.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4 - Mean SaO2 during Wake (n = 24, 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.31" lower_limit="93.54" upper_limit="95.08"/>
                    <measurement group_id="O2" value="93.86" lower_limit="93.08" upper_limit="94.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 1, REM, Difference (Suvorexant - Placebo) of Least Squares Means</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.03</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.41</ci_lower_limit>
            <ci_upper_limit>0.47</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 1, Non-REM, Difference (Suvorexant - Placebo) of Least Squares Means</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.13</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.53</ci_lower_limit>
            <ci_upper_limit>0.27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 1, Wake, Difference (Suvorexant - Placebo) of Least Squares Means</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.21</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.61</ci_lower_limit>
            <ci_upper_limit>0.18</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 4, REM, Difference (Suvorexant - Placebo) of Least Squares Means</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.33</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.32</ci_lower_limit>
            <ci_upper_limit>0.98</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 4, Non-REM, Difference (Suvorexant - Placebo) of Least Squares Means</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.26</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.26</ci_lower_limit>
            <ci_upper_limit>0.78</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 4, Wake, Difference (Suvorexant - Placebo) of Least Squares Means</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.45</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.10</ci_lower_limit>
            <ci_upper_limit>0.80</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Arterial SaO2 During Total Sleep Time</title>
        <description>Evaluation of the effect of multiple dose suvorexant on mean oxygen saturation (SaO2) during total sleep time as measured by pulse oximetry. Lower SaO2 values are associated with sleep impairment. Total sleep time is the total of all rapid eye movement (REM) and non-REM sleep in a sleep episode.</description>
        <time_frame>Day 1 of each period</time_frame>
        <population>Twenty-four of the 25 participants were included in the primary evaluation of SaO2 and AHI data; one participant was excluded due to a protocol violation.</population>
        <group_list>
          <group group_id="O1">
            <title>Suvorexant (40 mg or 30 mg)</title>
            <description>Participants administered either a 40-mg or a 30-mg dose of suvorexant.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants administered placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Arterial SaO2 During Total Sleep Time</title>
          <description>Evaluation of the effect of multiple dose suvorexant on mean oxygen saturation (SaO2) during total sleep time as measured by pulse oximetry. Lower SaO2 values are associated with sleep impairment. Total sleep time is the total of all rapid eye movement (REM) and non-REM sleep in a sleep episode.</description>
          <population>Twenty-four of the 25 participants were included in the primary evaluation of SaO2 and AHI data; one participant was excluded due to a protocol violation.</population>
          <units>Percentage of Oxygen Saturation</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.14" lower_limit="92.28" upper_limit="94.00"/>
                    <measurement group_id="O2" value="93.24" lower_limit="92.37" upper_limit="94.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Difference (Suvorexant - Placebo) of Least Squares Means</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.10</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.50</ci_lower_limit>
            <ci_upper_limit>0.31</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 14 days after last dose</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Suvorexant (40 mg)</title>
          <description>Participants administered a 40-mg dose of suvorexant.</description>
        </group>
        <group group_id="E2">
          <title>Suvorexant (30 mg)</title>
          <description>Participants administered a 30-mg oral dose of suvorexant.</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Participants administered placebo.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle tightness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Vice President, Late Stage Development Group Leader</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

